Actively Recruiting
Evaluation of Rupatifen Fumarate Capsules Compared to Rupatadine and Placebo in Adults with Seasonal Allergic Rhinitis
Led by Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Updated on 2026-09-09
550
Participants Needed
18
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Rupatifen Fumarate Capsules for adults aged 18 to 65 with seasonal allergic rhinitis. This phase 3 randomized, double-blind trial compares Rupatifen Fumarate Capsules to Rupatadine Fumarate Tablets and placebo capsules. The study aims to assess the effectiveness and safety of these treatments in relieving nasal and ocular symptoms caused by seasonal allergies during active symptomatic episodes. Participants are randomly assigned to one of three groups receiving Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets, or matching placebos. All treatments are taken orally once daily at a consistent time for 14 consecutive days. The study includes a 1-week run-in period before treatment to ensure symptom stability and proper diary completion. During the study, participants will complete symptom diaries and undergo physical exams, vital sign monitoring, laboratory tests, and electrocardiograms at screening, day 1, day 8, and day 15. Researchers will measure changes in nasal and ocular symptoms using reflective and instant Total Nasal Symptom Scores and quality of life questionnaires. Safety assessments will continue for about 7 days after the last dose. The total participation lasts approximately 3 weeks including run-in, treatment, and follow-up.
CONDITIONS
Brief Title
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
Research Team
X
Xiuzhen Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here